Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer

Clinical Cancer Research

Volumn 2, Issue 6, 1996, Pages 941-945

  Sekine, Ikuo ^a   Nishiwaki, Yutaka ^a   Watanabe, Koshiro ^b   Yoneda, Shuichi ^c   Saijo, Nagahiro ^d,e  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

^c SAITAMA CANCER CENTER   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RANITIDINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL;

EID: 0029948641     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Wani, M. C., Taylor, H. L., Wall, M E., Coggon, P., and McPhail, A. T. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Texas brevifolia. J. Am. Chem. Soc., 93, 2325-2327, 1971.
2. Rowinsky, E. K., Cazenave, L. A., and Donehower, R. C. Taxol: a novel investigational antimicrotubule agent. J. Natl. Cancer Inst., 82: 1247-1259, 1990.
3. Schiff, P. B., Fant, J., and Horwitz, S. B. Promotion of microtubule assembly in vitro by Taxol. Nature (Lond.), 22: 665-667, 1979.
4. Schiff, P. B., and Horwitz, S. B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA, 77: 1561-1565, 1980.
5. Rose, W. C. Taxol: a review of its preclinical in vivo antitumor activity. Anticancer Drugs, 3: 311-321, 1992.
6. ®). Semin. Oncol., 20 (Suppl. 3); 31-39, 1993.
7. Kris, M. G., O'Connell, J. P., Gralla, R. J., Wertheim, M. S., Parente, R. M., Schiff, P. B., and Young, C. W. Phase I trial of Taxol given as a 3 h infusion every 21 days. Cancer Treat. Rep., 70: 605-607, 1986.
8. Schiller, J. H., Storer, B., Tutsch, K., Arzoomanian, R., Alberti, D., Feierabend, C., and Spriggs, D. Phase I trial of 3 h infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J. Clin. Oncol., 12: 241-248, 1994.
9. Eisenhauer, E. A., Huinink, W. W. B., Swenerton, K. D., Gianni, L., Myles, J., van der Burg, M. E., Kerr, I., Vermorken, J. B., Buser, K., Colombo, N., Bacon, M., Santabarbara, P., Onetto, N., Winograd, B., and Canetta, R. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J. Clin. Oncol., 12: 2654-2666, 1994.
10. Klaassen, U., Diergarten, K., Dittrich, C. H., Kaufmann J., Sauter, C. H., and Seeber, S. Randomized trial of two doses of Taxol in metastatic breast cancer: an interim analysis. Onkologie, 17: 86-90, 1994.
11. Tamura, T., Sasaki, Y., Eguchi, K., Shinkai, T., Ohe, Y., Nishio, M., Kunikane, H., Arioka, H., Karato, A., Omatsu, H., Nakashima, H., and Saijo, N. Phase I and pharmacokinetic study of paclitaxel by 24 h intravenous infusion. Jpn. J. Cancer Res., 85: 1057-1062, 1994.
12. Tamura, T., Sasaki, Y., Nishiwaki, Y., and Saijo N. Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities. Jpn. J. Cancer Res., 86: 1203-1209, 1995.
13. Kuroishi, T., Hirose, K., Tominaga, S., Ogawa, H., and Tajima, K. Prediction of future cancer mortality in Japan. Jpn. J. Clin. Oncol., 22: 365-369, 1992.
14. Yokes, E. E., Vijiayakumar, S., Bitran, J. D., Hoffman, P. C., and Golomb, H. M. Role of systemic chemotherapy in advanced non-small cell lung cancer. Am. J. Med., 89: 777-785, 1990.
15. Murphy, W. K., Fossella, F. V., Winn, R. J., Shin, D. M., Hynes, H. E., Gross, H. M., Davilla, E., Leimert, J., Dhingra, H., Raber, M. N., Krakoff I. H , and Hong W. K. Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J. Natl. Cancer Inst., 85: 384-388, 1993.
16. Chang, A. Y., Kim, K., Glick, J., Anderson, T., Karp, D., and Johnson, D. Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group results J. Natl. Cancer Inst., 85: 388-394, 1993.
17. Ohtsu, T., Sasaki, Y., Tamura, T., Miyata, Y., Nakanomyo, H., Nishiwaki, Y., and Saijo, N. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-h infusion versus a 24-h infusion. Clin. Cancer Res., 1: 599-606, 1995.
18. Japan Society for Cancer Therapy. Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J. Jpn. Soc. Cancer Ther., 28: 101-130, 1993.
19. ®) in human tumor cell lines. Br. J. Cancer. 68: 1104-1109, 1993.
20. Lopes, N. M., Adams, E. G., Pitts, T. W., and Bhuyan, B. K. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother. Pharmacol., 32: 235-242, 1993.
21. Thigpen, J. T., Blessing, J. A., Ball, H., Hummel, S. J., and Barrett. R. J. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a gynecologic oncology group study. J. Clin. Oncol., 12: 1748-1753, 1994.
22. Trimble, E. L., Adams, J. D., Veno, D., Hawkins, M. J., Friedman, M. A., Fisherman, J. S., Christian, M. C., Canetta, R., Onetto, N., Hayn, R., and Arbuck, S. G. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J. Clin. Oncol., 11: 2405-2410, 1993.